A. Louis Bourgeois - Concepedia

Author

A. Louis Bourgeois

Also Known As

A Bourgeois, A L Bourgeois, A Louis Bourgeois, A. Bourgeois, A. L. BOURGEOIS, A. L. Bourgeois, A. LOUIS BOURGEOIS, A. Louis Bourgeois, A.L. Bourgeois, A.Louis Bourgeois

145

Publications

6.1K

Citations

H-Index

101

Concepts

All Affiliations

Johns Hopkins University Naval Medical Research Command Program for Appropriate Technology in Health Walter Reed Army Institute of Research United States Naval Medical Research Unit SOUTH

About

A. Louis Bourgeois is an author at Johns Hopkins University specializing in medicine, infection control, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	46	2.6K
2	Health Sciences	6	6	320
3	Public Health	6	6	293
4	Allergy	6	6	193
5	Engineering	3	3	40

A. Louis Bourgeois

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Diarrheal Disease during Operation Desert Shield Kenneth C. Hyams, A. Louis Bourgeois, B R Merrell, New England Journal of Medicine	1991	254
<i>Campylobacter jejuni</i>Cytolethal Distending Toxin Mediates Release of Interleukin-8 from Intestinal Epithelial Cells Thomas E. Hickey, Annette L. McVeigh, Daniel A. Scott, Infection and Immunity	2000	250
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial Sarah A. Frech, Herbert L. DuPont, A. Louis Bourgeois, The Lancet Microbial ToxinAntimicrobial SusceptibilityHeat-labile ToxinEscherichia ColiTraveler Diarrhea	2008	204
Mutation in the <i>peb1A</i> Locus of <i>Campylobacter jejuni</i> Reduces Interactions with Epithelial Cells and Intestinal Colonization of Mice Zhiheng Pei, Christophe Burucoa, B Grignon, Infection and Immunity DysbiosisMicrobial PathogensHost-microbe InteractionsBacteriologyBacterial Pathogens	1998	204
Mixed Cytomegalovirus Glycoprotein B Genotypes in Immunocompromised Patients A. Coaquette, A. Louis Bourgeois, C. Dirand, Clinical Infectious Diseases Primary ImmunodeficiencyTransplantationAutoimmune DiseaseViral PersistenceCmv Disease	2004	177
Status of vaccine research and development for enterotoxigenic Escherichia coli A. Louis Bourgeois, Thomas F. Wierzba, Richard I. Walker Vaccine VaccinationVaccine SafetyCross-protectionProtein SubunitsMucosal Vaccination	2016	154
A RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY OF RIFAXIMIN COMPARED WITH PLACEBO AND WITH CIPROFLOXACIN IN THE TREATMENT OF TRAVELERS’ DIARRHEA David N. Taylor, A. Louis Bourgeois, Charles D. Ericsson, American Journal of Tropical Medicine and Hygiene Health SciencesAntimicrobial StewardshipAntibioticsPharmacologyGastroenterology	2006	149
Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): Protective efficacy in a double-blind, placebo-controlled challenge study Robin McKenzie, A. Louis Bourgeois, Sarah A. Frech, Vaccine Microbial ToxinAntimicrobial SusceptibilityEnterotoxigenic Escherichia ColiImmunologyInfection Control	2007	125
<i>Campylobacter jejuni</i> -Stimulated Secretion of Interleukin-8 by INT407 Cells Thomas E. Hickey, Shihida Baqar, A. Louis Bourgeois, Infection and Immunity	1999	115
Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. Coli diarrhoea of travellers to Guatemala and Mexico David A. Sack, Janet Shimko, Olga Torres, Vaccine VaccinationVaccine SafetyPreventive MedicineGastrointestinal VirusKilled Oral Vaccine	2007	112

Page 1